NewAmsterdam Pharma Company N.V. (NAMS)

Market Cap	1.78B
Revenue (ttm)	15.66M
Net Income (ttm)	-196.60M
Shares Out	89.27M
EPS (ttm)	-2.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	140,101
Open	19.21
Previous Close	19.44
Day's Range	19.21 - 20.32
52-Week Range	5.63 - 26.35
Beta	0.02
Analysts	Strong Buy
Price Target	33.25 (+66.83%)
Earnings Date	Mar 31, 2023

About NAMS

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in N...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: NAMS

Financial Performance

In 2023, NAMS's revenue was 14.09 million, a decrease of -86.28% compared to the previous year's 102.69 million. Losses were -176.94 million, 681.7% more than in 2022.

Financial numbers in EUR

Analyst Forecast

According to 4 analysts, the average rating for NAMS stock is "Strong Buy." The 12-month stock price forecast is $33.25, which is an increase of 66.83% from the latest price.

Price Target

$33.25

(66.83% upside)

Analyst Consensus: Strong Buy